BYOD vs. Provisioned Devices for eCOA: Which Is Right for Your Trial?

When a study team builds out an eCOA plan, one of the first practical decisions is also one of the most consequential: should patients complete assessments on their own smartphone, or on a device the trial provides? This choice, often shorthanded as BYOD versus provisioned devices, shapes enrollment speed, data quality, and total cost long before the first patient logs a symptom.

What BYOD and provisioned devices actually mean

• BYOD (bring your own device): patients use their personal smartphone or tablet, with the eCOA app delivered through a browser or a downloadable app.
• Provisioned devices: the sponsor or CRO supplies a dedicated device, configured and locked down for the study, often shipped to the patient's home or handed out during a site visit.

The case for BYOD

• Faster enrollment, since there is no device provisioning, shipping, or import and export logistics to manage across countries.
• Lower hardware cost, with no device purchase, replacement, or reclamation budget.
• A familiar experience, since patients use an interface and device they already know, which supports timely, in-the-moment reporting rather than delayed recall entries.
• Easier scaling for large or geographically dispersed studies.

The case for provisioned devices

• A consistent hardware and software environment across every patient and site, which simplifies validation and support.
• No dependence on a patient owning a compatible smartphone or having reliable mobile data access.
• Less variability tied to screen size, operating system version, or app store availability across countries.
• Often preferred for populations that are older, have limited digital literacy, or are enrolled in decentralized, pediatric, or rare disease studies where device access cannot be assumed.

Compliance and regulatory considerations

Both approaches can meet 21 CFR Part 11 and ICH E6(R3) expectations for electronic data capture, but the validation burden differs. BYOD requires assessing a wider range of device and operating system combinations, while provisioned devices concentrate validation on a smaller, controlled set.

Data privacy is also a factor. BYOD implementations should keep study data isolated from personal apps and content on the patient's device, typically through a dedicated, sandboxed app rather than mixing with personal content. Source data and audit trail requirements apply equally regardless of device ownership, but device management such as patching, connectivity, and timezone handling is easier to standardize on provisioned hardware.

Patient population and study design factors

• Age and digital comfort: younger, tech-comfortable populations tend to do well with BYOD, while older populations or those with limited smartphone ownership often need provisioned devices.
• Geography: multi-country trials with variable mobile data infrastructure sometimes rely on provisioned devices with offline data capture and sync.
• Therapeutic area: rare disease and pediatric studies, where a caregiver may be reporting rather than the patient, often benefit from a consistent, provisioned interface.
• Trial duration and visit frequency: shorter studies may tolerate BYOD's device variability better than long-running studies where that variability compounds over time.

For a deeper look at how accessibility and multilingual analytics shape eCOA design choices across these populations, see our companion piece on accessibility-first ePRO design and multilingual analytics.

Cost comparison

BYOD avoids the capital cost of devices, shipping, and reclamation, but it may need broader compatibility testing and support paths for a wider range of consumer hardware and operating system versions. Provisioned devices carry upfront hardware and logistics costs but reduce variability-related support tickets and validation cycles later in the study.

Many sponsors find that above a certain enrollment size, the fixed cost of provisioned hardware is offset by lower per-patient support overhead. Below that threshold, BYOD is usually the more economical path.

A hybrid approach is often the practical answer

Many current trials do not choose one model exclusively. It is common to offer BYOD as the default while keeping a small pool of provisioned devices available for patients who do not have a compatible smartphone or reliable connectivity. This BYOD-first, provisioned-as-needed model can capture most of BYOD's cost and speed advantages while still meeting the population wherever it is.

Questions to ask before you decide

1. What proportion of your target population owns a compatible smartphone?
2. How many countries and operating system versions will the trial need to support?
3. Is the population likely to need caregiver-assisted or provisioned reporting, such as in pediatric, rare disease, or cognitive impairment studies?
4. What is your projected enrollment size, and does it change the cost calculus?
5. Does your eCOA vendor support a mixed BYOD and provisioned model within the same protocol?

Choosing what fits your protocol

There is no single right answer here, only the right answer for a specific protocol and population. Curebase's eCOA platform is built to support both BYOD and provisioned device strategies within the same study, so sponsors and CROs can match the approach to their patients rather than forcing patients to match the technology.

For a broader vendor landscape, our Top 5 ePRO/eCOA Platforms comparison is a good next read.